Dechert Advises Royalty Pharma on its Acquisition of Prevymis Royalties

 
June 09, 2020

Dechert advised Royalty Pharma on its acquisition of a partial royalty interest in Prevymis™ (letermovir) from AiCuris Anti-infective Cures GmbH. The US$220 million transaction played a significant role in the lead up to Royalty Pharma’s record-setting IPO.

Prevymis™ is an oral or injectable drug therapy approved by the U.S. Food and Drug Administration for prophylaxis of cytomegalovirus infection and disease in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant. The acquisition was noteworthy by providing further evidence of the strength of Royalty Pharma’s portfolio in advance of the company’s IPO on June 15, 2020, the largest IPO of the year thus far – and the second largest pharma IPO ever. While Dechert did not handle the IPO, the firm’s continued IP work on Royalty Pharma deals over the past two years helped make the IPO a success.

The Dechert team, which handled patent diligence on the transaction, was led by intellectual property partner Carl Morales, Ph.D., and included IP associates Blaine M. Hackman, Ph.D., and Vi Tran, Ph.D., and patent agent Todd Macklin, Ph.D.

About Dechert

Dechert is a leading global law firm with 26 offices around the world. We advise on matters and transactions of the greatest complexity, bringing energy, creativity and efficient management of legal issues to deliver commercial and practical advice for clients.

Subscribe to Dechert Updates